联环药业：获得2类改良新药LH-2417片临床试验批准通知书

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its modified new drug LH-2417, aimed at treating benign prostatic hyperplasia in men [2] Group 1: Company Developments - Lianhuan Pharmaceutical announced the approval of the clinical trial for LH-2417, which is intended for the initial treatment of symptoms associated with benign prostatic hyperplasia [2] - The company has invested approximately 1.3678 million yuan in the research and development of this drug [2] - Due to the lengthy development cycle and potential uncertainties associated with modified new drugs, it is expected that there will be no significant impact on the company's revenue and operating performance in the short term [2]